Industry shutdowns are messy and painful: 4 lessons Australia’s coal sector can learn from car-makers about bowing out 
Type 2 diabetes is not one-size-fits-all: Subtypes affect complications and treatment options 
Hyundai Halts Advertising on X Amid Antisemitism Row 
Eating some chocolate really might be good for you – here’s what the research says 
LVMH Adds Bernard Aranault’s Sons Frederic and Alexandre Arnault to the Board 
Honey is said to help with hay fever symptoms – here’s what the research says about this claim 
Why the government’s haste in changing the health system could come back to haunt it 
Orbital resonance − the striking gravitational dance done by planets with aligning orbits 
Death doulas: helping people at the end of their life 
Traditional Japanese diet associated with less brain shrinkage in women compared to western diet, says research 
If life exists on Jupiter’s moon Europa, scientists might soon be able to detect it 
EU enlargement: What does the future hold? 
The hidden racist history of hair loss 
How India’s economy has fared under ten years of Narendra Modi 
The idea that US interest rates will stay higher for longer is probably wrong 
South Korea’s JW Pharmaceutical has received a patent in Russia for a hair loss treatment currently under development, marking the first time that its candidate drug has been patented overseas.
The pharmaceutical firm received a patent for JW0061, its Wnt-targeted hair loss treatment, from Russia's Federal Service for Intellectual Property.
The patent covers a new heterocyclic inducer of the Wnt signaling pathway, including its base or isomer, and compositions containing it as an active ingredient.
JW has also submitted patent applications in more than ten nations, including the US, EU, Japan, and China.
JW0061 exhibits a novel method of action by directly binding to the GFRA1 protein in human hair dermal papilla cells, activating the Wnt signaling pathway. This is the first instance of a low-molecular-weight medication that describes the mechanism of hair growth that has been documented.
JW is now evaluating non-clinical toxicity in accordance with good laboratory practice with the intention of initiating clinical trials for JW0061 in the first half of 2024. Additionally, it collaborates on research projects with eminent dermatologists in the US.
JW plans to develop JW0061 as a new innovative drug that supplements or replaces existing hair loss treatments.
